Micromet, Inc (f/k/a MITI)

[DocLee]

The National Cancer Institute Shows Confidence in Blinatumomab.

The NCI has signed a Co-operative Research & Development Agreement (CRADA) with Micromet to progress blinatumomab's development against B-Cell-derived haematologic malignancies (lymphoblastic leukaemia and various lymphomas). Initially this will be in trials using blinatumomab as first-line therapy in newly diagnosed patients.

This is one more (large) piece of evidence that blinatumomab is being recognised as a significant new treatment in haematologic malignancies.

It is becoming increasingly clear that BiTE antibody therapy has a bright future ahead and this can only be good for Micromet.

Press Release